Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add filters








Language
Year range
1.
Clinical Psychopharmacology and Neuroscience ; : 68-69, 2017.
Article in English | WPRIM | ID: wpr-41575

ABSTRACT

Disulfiram is the commonly prescribed drug for the treatment of alcohol dependence. It's major metabolite (diethyldithiocarbamate) is an inhibitor of dopamine-betahydroxylase, an enzyme that catalyzes the metabolism of dopamine to norepinephrine resulting in psychosis. We recommend that disulfiram should be used at the lowest effective dose, possibly 250 mg daily and caution should be taken while prescribing disulfiram for patients with personal and familial antecedents of psychosis.


Subject(s)
Humans , Alcoholism , Disulfiram , Dopamine , Metabolism , Norepinephrine , Psychotic Disorders
2.
Clinical Psychopharmacology and Neuroscience ; : 218-220, 2016.
Article in English | WPRIM | ID: wpr-175040

ABSTRACT

Tardive dyskinesia is one of the most significant side effects of antipsychotic medications. Antipsychotic treated schizophrenia patients with diabetes mellitus are more likely to develop tardive dyskinesia than those without diabetes. Clozapine is probably best supported for management of tardive dyskinesia. But clozapine has been strongly linked to hyperglycaemia and impaired glucose tolerance, so it is not preferred in patients with diabetes mellitus. We present a case of 35-year-old male with a diagnosis of schizophrenia and type 2 diabetes mellitus with tardive dyskinesia, who was successfully treated with quetiapine and clonazepam.


Subject(s)
Adult , Humans , Male , Clonazepam , Clozapine , Diabetes Mellitus , Diabetes Mellitus, Type 2 , Diagnosis , Glucose , Movement Disorders , Schizophrenia , Quetiapine Fumarate
SELECTION OF CITATIONS
SEARCH DETAIL